Shared on10 Oct 25Fair value Increased 1.29%
Medtronic's analyst price target has increased slightly to approximately $99.90, as analysts cite improved sector sentiment, recent company developments, and opportunities identified in Medtronic's product pipeline and market positioning. Analyst Commentary Recent research notes have shown a mixture of optimism and caution regarding Medtronic's outlook.
Shared on27 Aug 25Fair value Increased 1.30%
Analysts have raised Medtronic’s price target to $98.44, citing activist involvement, operational improvements, and favorable policy developments, though some concerns about execution remain. Analyst Commentary Bullish analysts have raised price targets on expectations that Elliott Management's active involvement and the addition of independent directors will sharpen Medtronic's strategic focus and drive stronger growth initiatives.
Shared on30 Apr 25Fair value Increased 1.13%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Decreased 0.12%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.11%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 11%
AnalystConsensusTarget has increased future PE multiple from 22.8x to 25.4x.
Shared on10 Mar 25Fair value Decreased 8.96%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.